Alpha Cognition Inc. Comm... (ACOG)
NASDAQ: ACOG
· Real-Time Price · USD
9.00
0.60 (7.14%)
At close: Sep 05, 2025, 3:59 PM
8.91
-1.00%
After-hours: Sep 05, 2025, 05:23 PM EDT
Company Description
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury.
It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.
The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021.
Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Alpha Cognition Inc. Common Stock
| Country | CA |
| IPO Date | n/a |
| Industry | Financial - Conglomerates |
| Sector | Financial Services |
| Employees | 5 |
| CEO | Michael E. McFadden |
Contact Details
Address: 750 West Pender Street Vancouver, BC CA | |
| Website | https://www.alphacognition.com |
Stock Details
| Ticker Symbol | ACOG |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001655923 |
| CUSIP Number | n/a |
| ISIN Number | CA02074J5017 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael E. McFadden B.B.A. | Chief Executive Officer & Director |
| Lauren D'Angelo M.B.A. | Chief Operating Officer |
| Dr. Denis G. Kay Ph.D. | Chief Scientific Officer |
| Kenneth Anthony Cawkell B.A., LL.B. | Founder, Consultant, Corporate Secretary & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 29, 2025 | 424B2 | Filing |
| Aug 29, 2025 | 424B3 | Filing |
| Aug 22, 2025 | 8-K | Current Report |
| Aug 22, 2025 | S-3 | Filing |
| Aug 21, 2025 | 4 | Filing |
| Aug 20, 2025 | 4 | Filing |
| Aug 20, 2025 | 4 | Filing |
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Aug 05, 2025 | 424B3 | Filing |
| Jul 21, 2025 | S-3 | Filing |